Cogent Biosciences
Cogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Positive results from registration-directed trials in NonAdvanced SM, Advanced SM and GIST were reported in 2025. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2.
Is Cogent Biosciences hiring?
Yes — Cogent Biosciences has 16 open jobs on JobsRadar right now, across 16 departments and 3 locations. 1 of them were opened in the last 30 days. 14 of them disclose pay, with a median of $206,250 a year and most offers between $193,125 and $221,875. The board was last refreshed on August 23, 2026 at 11:52 UTC.
Frequently asked questions
- Is Cogent Biosciences hiring?
- Yes. Cogent Biosciences has 16 open jobs on JobsRadar as of August 23, 2026. 1 of them were opened in the last 30 days.
- What roles is Cogent Biosciences hiring for?
- Cogent Biosciences is hiring for roles in Medical Affairs, Chemistry, CMC and Development Operations.
- What does Cogent Biosciences pay?
- Across the 14 Cogent Biosciences jobs that disclose pay, the median is $206,250 a year, and most offers fall between $193,125 and $221,875.
- How current are these listings?
- Every listing comes straight from the employer’s own careers system and is re-checked three times a day. This page was last updated on August 23, 2026 at 11:52 UTC.